October 9, 2020 -- The Association for Molecular Pathology (AMP) has released the preliminary results of its August 2020 SARS-CoV-2 testing survey for clinical laboratories showing labs continue to experience supply chain interruptions and are now also facing significant staffing shortages. However, the demand for molecular diagnostic testing has increased.
The 100-question survey assessed several aspects of testing SARS-CoV-2: sample types, patient populations, methodologies, validation, performance, supply chain, public health reporting, laboratory workforce, and reimbursement. The survey responses came from 113 representatives affiliated with U.S.-based academic medical centers, commercial reference laboratories, public health laboratories, and community hospitals.
More than half (54%) of the respondents said testing demand was currently higher than their capacity, and they anticipate demand will continue to rise, especially with the fall and winter influenza season.
While demand keeps rising, staffing has not -- 85% of respondents have shortages and 66% do not have enough qualified clinical laboratory technologists/scientists. In addition, more than half (53%) do not have enough clinical laboratory technicians.
Based on the most recent survey results, as well as an earlier April survey, the AMP has two new recommendations:
The AMP's previous five recommendations still stand:
The AMP will continue to review the pandemic's effects on clinical practice, regulatory policy, and reimbursement.
"These survey results will be fundamental to informing potential legislation and other initiatives that could significantly improve response to the current and future pandemics," said Dr. Karen Weck, AMP president and director of the molecular genetics lab at the University of North Carolina Chapel Hill.